The results could help guide the design of new vaccines for the disease.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.

A small subset of uninfected people also had SARS-CoV-2-fighting T cells, a finding that scientists are still trying to figure out.

While the finding doesn’t prove people become immune to the virus after infection, it is good news for vaccine development.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

High salt concentrations are present in the affected skin of people with atopic dermatitis and promote the differentiation of the T helper cells involved in the development of allergic diseases.

The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy.

The assay screens for latent virus that has the capacity to activate if antiretroviral therapy stops.